Anlotinib-related hyperlipidemia in predicting the efficacy of anlotinib in treatment for advanced lung cancer
[ABSTRACT]AIM To evaluate the clinical efficacy of anlotinib treatment in advanced lung cancer and its correlation with hyperlipidemia.METHODS A total of 75 patients with advanced lung cancer treated from January 2019 to December 2023 were enrolled in the retrospective study.Basic clinical characteristics and blood lipid levels,including total cholesterol,triglycerides,low-density lipoprotein cholesterol(LDL-C),and high-density lipoprotein cholesterol(HDL-C)were recorded at baseline and before each treatment.According to the lipid changes,they were divided into non-hyperlipidemia group and hyperlipidemia group.Differences in disease control rate(DCR),disease remission rate(ORR),progression-free survival(PFS)and overall survival(OS)between 2 groups were observed.RESULTS The ORR for the entire study population was 16％and the DCR was 81.33％.The median PFS and median OS were 4.77 months(95％CI:3.515-6.019)and 7.83 months(95％CI:6.420-9.247),respectively.The incidence of treatment-associated hyperlipidemia with anlotinib in this study was 48％(36/75).Compared with the non-hyperlipidemia group,patients in the hyperlipidemia group had higher DCR(100％vs 73.1％,P＜0.05),and longer PFS(6.2 vs 3.87 months,P＜0.05).Multifactorial analysis showed that patients'ECOG score of 0-1 and adoption of combined treatment modality were independent protective factors for PFS.ECOG score of 0-1 and LDL-C level of≥3.40 mmol·L-1 were independent protective factors for OS,and HDL-C level of＜1.00 mmol·L-1was regarded as an independent risk factor for PFS and OS.CONCLUSION The presence of hyperlipidemia induced by anlotinib may be a potential clinical marker for predicting the efficacy of anlotinib in treating advanced lung cancer.
anlotinibhyperlipidemiaadvanced lung cancerefficacy predictionretrospective study
国家科技期刊平台
NSTL
万方数据
